Investment analysts at Oppenheimer began coverage on shares of Outlook Therapeutics (NASDAQ:OTLK) in a research report issued to clients and investors on Thursday, Marketbeat reports. The firm set an “outperform” rating and a $12.00 price target on the stock. Oppenheimer’s price target indicates a potential upside of 471.43% from the company’s current price.
OTLK has been the topic of a number of other reports. ValuEngine upgraded Outlook Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, March 20th. Ascendiant Capital Markets initiated coverage on Outlook Therapeutics in a research note on Monday, April 22nd. They issued a “buy” rating and a $4.00 price objective on the stock.
Shares of Outlook Therapeutics stock traded up $0.57 during trading on Thursday, reaching $2.10. The company’s stock had a trading volume of 76,333,495 shares, compared to its average volume of 3,464,738. Outlook Therapeutics has a one year low of $0.85 and a one year high of $10.96.
Outlook Therapeutics (NASDAQ:OTLK) last posted its quarterly earnings data on Wednesday, May 15th. The company reported ($0.58) EPS for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.08. The business had revenue of $0.64 million during the quarter.
A hedge fund recently bought a new stake in Outlook Therapeutics stock. Renaissance Technologies LLC acquired a new position in Outlook Therapeutics, Inc. (NASDAQ:OTLK) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 11,166 shares of the company’s stock, valued at approximately $83,000. Renaissance Technologies LLC owned 0.10% of Outlook Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 4.60% of the company’s stock.
About Outlook Therapeutics
Outlook Therapeutics, Inc, a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases.
Featured Article: Quiet Period Expirations Explained
Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.